
Benzinga Pro data, Akebia Therapeutics (NASDAQ:AKBA) reported Q4 sales of $59.60 million. Earnings fell to a loss of $70.68 million, resulting in a 18.7% decrease from last quarter. In Q3, Akebia Therapeutics brought in $48.76 million in sales but lost $59.54 million in earnings.